Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial.

ABSTRACT:

Background

The BICNOW clinical trial evaluated the effectiveness, safety, satisfaction, adherence to treatment, and retention in the system of a rapid initiation strategy with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in naïve HIV-infected individuals. It also assessed the burden of this infection on individuals and healthcare systems using various instruments, participant questionnaires, and pharmacoeconomic evaluations of this antiretroviral therapy (ART). This substudy focused on changes in the health-related quality of life (HRQoL) of participants and on the economic impact of this rapid initiation strategy.

Methods and findings

Patients were recruited for this phase IV, multicenter, open, single-branch clinical trial with 48-week follow-up between No

SUBMITTER: Sequera-Arquelladas S 

PROVIDER: S-EPMC12453196 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature